Want to see IART full AI Analyst Report?
IART Stock Chart & Stats
$11.14
-$0.23(-1.04%)
At close: 4:00 PM EST
$11.14
-$0.23(-1.04%)
Day’s Range― - ―
52-Week Range$8.70 - $18.92
Previous CloseN/A
Volume73.30K
Average Volume (3M)682.69K
Market Cap
$1.46B
Enterprise Value$3.14B
Total Cash (Recent Filing)$265.50M
Total Debt (Recent Filing)$2.04B
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Jul 29, 2026EPS Estimate
0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.48
Shares Outstanding77,796,906
10 Day Avg. Volume691,147
30 Day Avg. Volume682,692
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-21.06
Enterprise Value/Market Cap2.15
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda-10.86
Forecast
1Y Price Target
$19.40Price Target Upside74.15% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)2.44
Revenue Forecast (FY)$1.68B
Bulls Say, Bears Say
Bulls Say
Leadership And TurnaroundThere is potential for a multi-year turnaround under new leadership if regulatory issues are managed effectively.
Revenue PerformanceTotal revenues of $383 million were slightly above consensus of $381 million and within the midpoint of guidance.
Bears Say
Guidance And EstimatesThe company's estimates continue to have a downward bias, making it challenging to predict future performance accurately.
Operational ChallengesThe company is facing ongoing issues with shipholds and capacity, which are affecting its overall performance.
Regulatory And ComplianceThere is a cautious outlook on the company's shares due to concerns about structural damage from extended shipholds and compliance issues.
Integra Lifesciences News
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $8.70 and its highest was $18.92 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is $1.46B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Jul 29, 2026 which is in 29 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on May 05, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.405 by $0.135.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Undervalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. does not currently pay dividends.
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.48.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,796,906 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.54 in its last earnings report, beating expectations of $0.405. Following the earnings report the stock price went up 24.131%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in IART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integra Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.40 (74.15% Upside)
$19.40 (74.15% Upside)
Blogger Sentiment
Bullish
IART Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 143.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.65%
12-Months-Change
Fundamentals
Return on Equity
-47.65%
Trailing 12-Months
Asset Growth
-11.72%
Trailing 12-Months
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
IART Company Deck
IART Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear positive developments: a revenue and EPS beat in Q1, meaningful margin expansion, strong growth in Tissue Reconstruction (notably Integra Skin, DuraSorb and PriMatrix), improved operating cash flow, and decisive leadership and commercial alignment actions (CEO transition and new CCO). At the same time, the company faces notable challenges including pockets of organic decline in Specialty Surgery, ongoing remediation with some products off-market, negative free cash flow in the quarter, elevated net leverage (4.1x) and modest full-year organic growth guidance. Overall, the positives — operational improvements, margin gains, guidance maintained with a small EPS lift, and clear product/commercial catalysts (Braintree restart, SurgiMend relaunch, PMA pathway) — outweigh the near-term headwinds, though risks remain around product returns, cash conversion and leverage.View all IART earnings summariesIART Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$19.40
▲(74.15% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
3.27% Insiders
30.26% Mutual Funds
27.34% Other Institutional Investors
12.68% Public Companies and
Individual Investors








